{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:59:11Z","timestamp":1793383151400,"version":"4.5.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T00:00:00Z","timestamp":1749168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T00:00:00Z","timestamp":1749168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1038\/s41591-025-03723-6","type":"journal-article","created":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T05:03:09Z","timestamp":1749186189000},"page":"2317-2324","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Adjunct-to-insulin therapy using SGLT2 inhibitors in youth with type 1 diabetes: a randomized controlled trial"],"prefix":"10.1038","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3557-3584","authenticated-orcid":false,"given":"Farid H.","family":"Mahmud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petter","family":"Bjornstad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheril","family":"Clarson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1800-2333","authenticated-orcid":false,"given":"Samantha J.","family":"Anthony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Curtis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3400-2805","authenticated-orcid":false,"given":"Yesmino T.","family":"Elia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynne","family":"McArthur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7308-1268","authenticated-orcid":false,"given":"Luc","family":"Mertens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahim","family":"Moineddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Kirsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Coles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Maione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Furman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Funmbi","family":"Babalola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalie L.","family":"Tommerdahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Harrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Riddell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4214-5465","authenticated-orcid":false,"given":"Pottumarthi","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lennox","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3126-3730","authenticated-orcid":false,"given":"Hiddo J. L.","family":"Heerspink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4164-0429","authenticated-orcid":false,"given":"David Z. I.","family":"Cherney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,6]]},"reference":[{"key":"3723_CR1","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S2213-8587(24)00155-4","volume":"12","author":"EM Apperloo","year":"2024","unstructured":"Apperloo, E. M. et al. Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol. 12, 545\u2013557 (2024).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"3723_CR2","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1007\/s13300-024-01550-5","volume":"15","author":"S Seidu","year":"2024","unstructured":"Seidu, S. et al. SGLT2 inhibitors\u2014the new standard of care for cardiovascular, renal and metabolic protection in type 2 diabetes: a narrative review. Diabetes Ther. 15, 1099\u20131124 (2024).","journal-title":"Diabetes Ther."},{"key":"3723_CR3","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/S2213-8587(19)30180-9","volume":"7","author":"O Mosenzon","year":"2019","unstructured":"Mosenzon, O. et al. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. Lancet Diabetes Endocrinol. 7, 606\u2013617 (2019).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"3723_CR4","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman, B. et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373, 2117\u20132128 (2015).","journal-title":"N. Engl. J. Med."},{"key":"3723_CR5","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1111\/dom.13301","volume":"20","author":"CCJ Dekkers","year":"2018","unstructured":"Dekkers, C. C. J. et al. Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers. Diabetes Obes. Metab. 20, 1988\u20131993 (2018).","journal-title":"Diabetes Obes. Metab."},{"key":"3723_CR6","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","volume":"134","author":"HJ Heerspink","year":"2016","unstructured":"Heerspink, H. J., Perkins, B. A., Fitchett, D. H., Husain, M. & Cherney, D. Z. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation 134, 752\u2013772 (2016).","journal-title":"Circulation"},{"key":"3723_CR7","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S2213-8587(19)30384-5","volume":"8","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink, H. J. L. et al. Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study. Lancet Diabetes Endocrinol. 8, 27\u201335 (2020).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"3723_CR8","doi-asserted-by":"publisher","first-page":"650","DOI":"10.2337\/dc21-1584","volume":"45","author":"A Palanca","year":"2022","unstructured":"Palanca, A., van Nes, F., Pardo, F., Ampudia Blasco, F. J. & Mathieu, C. Real-world evidence of efficacy and safety of SGLT2 inhibitors as adjunctive therapy in adults with type 1 diabetes: a European two-center experience. Diabetes Care 45, 650\u2013658 (2022).","journal-title":"Diabetes Care"},{"key":"3723_CR9","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1016\/S2213-8587(17)30308-X","volume":"5","author":"P Dandona","year":"2017","unstructured":"Dandona, P. et al. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol. 5, 864\u2013876 (2017).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"3723_CR10","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.2337\/dc18-0623","volume":"41","author":"C Mathieu","year":"2018","unstructured":"Mathieu, C. et al. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 24-week results from a randomized controlled trial. Diabetes Care 41, 1938\u20131946 (2018).","journal-title":"Diabetes Care"},{"key":"3723_CR11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00125-023-06015-1","volume":"67","author":"VS Sridhar","year":"2024","unstructured":"Sridhar, V. S. et al. Chronic kidney disease in type 1 diabetes: translation of novel type 2 diabetes therapeutics to individuals with type 1 diabetes. Diabetologia 67, 3\u201318 (2024).","journal-title":"Diabetologia"},{"key":"3723_CR12","doi-asserted-by":"publisher","first-page":"426","DOI":"10.2337\/dc17-1118","volume":"41","author":"T Costacou","year":"2018","unstructured":"Costacou, T. & Orchard, T. J. Cumulative kidney complication risk by 50 years of type 1 diabetes: the effects of sex, age, and calendar year at onset. Diabetes Care 41, 426\u2013433 (2018).","journal-title":"Diabetes Care"},{"key":"3723_CR13","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1111\/pedi.13444","volume":"23","author":"P Bjornstad","year":"2022","unstructured":"Bjornstad, P. et al. ISPAD Clinical Practice Consensus Guidelines 2022: microvascular and macrovascular complications in children and adolescents with diabetes. Pediatr. Diabetes 23, 1432\u20131450 (2022).","journal-title":"Pediatr. Diabetes"},{"key":"3723_CR14","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.diabres.2017.01.012","volume":"126","author":"KE Minges","year":"2017","unstructured":"Minges, K. E. et al. Correlates of overweight and obesity in 5529 adolescents with type 1 diabetes: the T1D Exchange Clinic Registry. Diabetes Res. Clin. Pract. 126, 68\u201378 (2017).","journal-title":"Diabetes Res. Clin. Pract."},{"key":"3723_CR15","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1089\/dia.2023.0320","volume":"25","author":"O Ebekozien","year":"2023","unstructured":"Ebekozien, O. et al. Longitudinal trends in glycemic outcomes and technology use for over 48,000 people with type 1 diabetes (2016\u20132022) from the T1D Exchange Quality Improvement Collaborative. Diabetes Technol. Ther. 25, 765\u2013773 (2023).","journal-title":"Diabetes Technol. Ther."},{"key":"3723_CR16","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.2337\/dc11-0167","volume":"34","author":"DZ Cherney","year":"2011","unstructured":"Cherney, D. Z. & Sochett, E. B. Evolution of renal hyperfiltration and arterial stiffness from adolescence into early adulthood in type 1 diabetes. Diabetes Care 34, 1821\u20131826 (2011).","journal-title":"Diabetes Care"},{"key":"3723_CR17","doi-asserted-by":"publisher","first-page":"845","DOI":"10.2337\/dc22-2003","volume":"46","author":"D Moriconi","year":"2023","unstructured":"Moriconi, D. et al. Glomerular hyperfiltration predicts kidney function decline and mortality in type 1 and type 2 diabetes: a 21-year longitudinal study. Diabetes Care 46, 845\u2013853 (2023).","journal-title":"Diabetes Care"},{"key":"3723_CR18","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.2337\/db08-1543","volume":"58","author":"PH Groop","year":"2009","unstructured":"Groop, P. H. et al. The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes. Diabetes 58, 1651\u20131658 (2009).","journal-title":"Diabetes"},{"key":"3723_CR19","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1111\/dom.13811","volume":"21","author":"RM Goldenberg","year":"2019","unstructured":"Goldenberg, R. M., Gilbert, J. D., Hramiak, I. M., Woo, V. C. & Zinman, B. Sodium-glucose co-transporter inhibitors, their role in type 1 diabetes treatment and a risk mitigation strategy for preventing diabetic ketoacidosis: the STOP DKA protocol. Diabetes Obes. Metab. 21, 2192\u20132202 (2019).","journal-title":"Diabetes Obes. Metab."},{"key":"3723_CR20","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1089\/dia.2018.0246","volume":"20","author":"SK Garg","year":"2018","unstructured":"Garg, S. K., Peters, A. L., Buse, J. B. & Danne, T. Strategy for mitigating DKA risk in patients with type 1 diabetes on adjunctive treatment with SGLT inhibitors: a STICH protocol. Diabetes Technol. Ther. 20, 571\u2013575 (2018).","journal-title":"Diabetes Technol. Ther."},{"key":"3723_CR21","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1111\/dom.12975","volume":"19","author":"T Biester","year":"2017","unstructured":"Biester, T. et al. Effects of dapagliflozin on insulin-requirement, glucose excretion and \u03b2-hydroxybutyrate levels are not related to baseline HbA1c in youth with type 1 diabetes. Diabetes Obes. Metab. 19, 1635\u20131639 (2017).","journal-title":"Diabetes Obes. Metab."},{"key":"3723_CR22","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1097\/MNH.0000000000000084","volume":"24","author":"M \u0160krti\u0107","year":"2015","unstructured":"\u0160krti\u0107, M. & Cherney, D. Z. Sodium-glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy. Curr. Opin. Nephrol. Hypertens. 24, 96\u2013103 (2015).","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"3723_CR23","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/S2213-8587(21)00242-4","volume":"9","author":"HJL Heerspink","year":"2021","unstructured":"Heerspink, H. J. L. et al. Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 9, 743\u2013754 (2021).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"3723_CR24","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1111\/j.1523-1755.2005.00590.x","volume":"68","author":"R Amin","year":"2005","unstructured":"Amin, R. et al. The relationship between microalbuminuria and glomerular filtration rate in young type 1 diabetic subjects: the Oxford Regional Prospective Study. Kidney Int. 68, 1740\u20131749 (2005).","journal-title":"Kidney Int."},{"key":"3723_CR25","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1093\/ndt\/gfv121","volume":"30","author":"P Bjornstad","year":"2015","unstructured":"Bjornstad, P. et al. Rapid GFR decline is associated with renal hyperfiltration and impaired GFR in adults with type 1 diabetes. Nephrol. Dial. Transplant. 30, 1706\u20131711 (2015).","journal-title":"Nephrol. Dial. Transplant."},{"key":"3723_CR26","first-page":"F85","volume":"241","author":"TH Hostetter","year":"1981","unstructured":"Hostetter, T. H., Olson, J. L., Rennke, H. G., Venkatachalam, M. A. & Brenner, B. M. Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation. Am. J. Physiol. 241, F85\u2013F93 (1981).","journal-title":"Am. J. Physiol."},{"key":"3723_CR27","first-page":"F667","volume":"314","author":"JA Lovshin","year":"2018","unstructured":"Lovshin, J. A. et al. Hyperfiltration, urinary albumin excretion, and ambulatory blood pressure in adolescents with type 1 diabetes mellitus. Am. J. Physiol. 314, F667\u2013F674 (2018).","journal-title":"Am. J. Physiol."},{"key":"3723_CR28","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1007\/s12325-023-02652-5","volume":"41","author":"S Verma","year":"2024","unstructured":"Verma, S., Mudaliar, S. & Greasley, P. J. Potential underlying mechanisms explaining the cardiorenal benefits of sodium-glucose cotransporter 2 inhibitors. Adv. Ther. 41, 92\u2013112 (2024).","journal-title":"Adv. Ther."},{"key":"3723_CR29","doi-asserted-by":"publisher","DOI":"10.1172\/JCI164486","volume":"133","author":"JA Schaub","year":"2023","unstructured":"Schaub, J. A. et al. SGLT2 inhibitors mitigate kidney tubular metabolic and mTORC1 perturbations in youth-onset type 2 diabetes. J. Clin. Invest. 133, e164486 (2023).","journal-title":"J. Clin. Invest."},{"key":"3723_CR30","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.2337\/diabetes.51.5.1580","volume":"51","author":"K Drummond","year":"2002","unstructured":"Drummond, K. & Mauer, M. The early natural history of nephropathy in type 1 diabetes: II. Early renal structural changes in type 1 diabetes. Diabetes 51, 1580\u20131587 (2002).","journal-title":"Diabetes"},{"key":"3723_CR31","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1111\/dom.14248","volume":"23","author":"M Phillip","year":"2021","unstructured":"Phillip, M. et al. Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: pooled 52-week outcomes from the DEPICT-1 and -2 studies. Diabetes Obes. Metab. 23, 549\u2013560 (2021).","journal-title":"Diabetes Obes. Metab."},{"key":"3723_CR32","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.2337\/dc18-1749","volume":"41","author":"J Rosenstock","year":"2018","unstructured":"Rosenstock, J. et al. Empagliflozin as adjunctive to insulin therapy in type 1 diabetes: the EASE trials. Diabetes Care 41, 2560\u20132569 (2018).","journal-title":"Diabetes Care"},{"key":"3723_CR33","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1111\/dom.14127","volume":"22","author":"HW Rodbard","year":"2020","unstructured":"Rodbard, H. W. et al. Sotagliflozin added to optimized insulin therapy leads to HbA1c reduction without weight gain in adults with type 1 diabetes: a pooled analysis of inTandem1 and inTandem2. Diabetes Obes. Metab. 22, 2089\u20132096 (2020).","journal-title":"Diabetes Obes. Metab."},{"key":"3723_CR34","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1111\/dom.12647","volume":"18","author":"J Parkinson","year":"2016","unstructured":"Parkinson, J., Tang, W., Johansson, C. C., Boulton, D. W. & Hamren, B. Comparison of the exposure\u2013response relationship of dapagliflozin in adult and paediatric patients with type 2 diabetes mellitus. Diabetes Obes. Metab. 18, 685\u2013692 (2016).","journal-title":"Diabetes Obes. Metab."},{"key":"3723_CR35","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1111\/bcp.13981","volume":"85","author":"D Busse","year":"2019","unstructured":"Busse, D. et al. Comparison of pharmacokinetics and the exposure\u2013response relationship of dapagliflozin between adolescent\/young adult and adult patients with type 1 diabetes mellitus. Br. J. Clin. Pharmacol. 85, 1820\u20131828 (2019).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"3723_CR36","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1111\/dom.12638","volume":"18","author":"GS Tirucherai","year":"2016","unstructured":"Tirucherai, G. S., LaCreta, F., Ismat, F. A., Tang, W. & Boulton, D. W. Pharmacokinetics and pharmacodynamics of dapagliflozin in children and adolescents with type 2 diabetes mellitus. Diabetes Obes. Metab. 18, 678\u2013684 (2016).","journal-title":"Diabetes Obes. Metab."},{"key":"3723_CR37","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1111\/dom.13945","volume":"22","author":"BA Perkins","year":"2020","unstructured":"Perkins, B. A. et al. Low-dose empagliflozin as adjunct-to-insulin therapy in type 1 diabetes: a valid modelling and simulation analysis to confirm efficacy. Diabetes Obes. Metab. 22, 427\u2013433 (2020).","journal-title":"Diabetes Obes. Metab."},{"key":"3723_CR38","doi-asserted-by":"publisher","first-page":"919","DOI":"10.2337\/dc18-2149","volume":"42","author":"T Danne","year":"2019","unstructured":"Danne, T. et al. Improved time in range and glycemic variability with sotagliflozin in combination with insulin in adults with type 1 diabetes: a pooled analysis of 24-week continuous glucose monitoring data from the inTandem program. Diabetes Care 42, 919\u2013930 (2019).","journal-title":"Diabetes Care"},{"key":"3723_CR39","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1089\/dia.2022.0248","volume":"24","author":"DJ DeSalvo","year":"2022","unstructured":"DeSalvo, D. J. et al. Transatlantic comparison of pediatric continuous glucose monitoring use in the Diabetes-Patienten-Verlaufsdokumentation Initiative and Type 1 Diabetes Exchange Quality Improvement Collaborative. Diabetes Technol. Ther. 24, 920\u2013924 (2022).","journal-title":"Diabetes Technol. Ther."},{"key":"3723_CR40","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1161\/CIRCULATIONAHA.111.077487","volume":"127","author":"JQ Purnell","year":"2013","unstructured":"Purnell, J. Q., Zinman, B. & Brunzell, J. D. The effect of excess weight gain with intensive diabetes mellitus treatment on cardiovascular disease risk factors and atherosclerosis in type 1 diabetes mellitus: results from the Diabetes Control and Complications Trial\/Epidemiology of Diabetes Interventions and Complications Study (DCCT\/EDIC) study. Circulation 127, 180\u2013187 (2013).","journal-title":"Circulation"},{"key":"3723_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/srep44128","volume":"7","author":"J Chen","year":"2017","unstructured":"Chen, J. et al. The efficacy and safety of SGLT2 inhibitors for adjunctive treatment of type 1 diabetes: a systematic review and meta-analysis. Sci. Rep. 7, 44128 (2017).","journal-title":"Sci. Rep."},{"key":"3723_CR42","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1007\/s00467-022-05827-4","volume":"38","author":"H Pottel","year":"2023","unstructured":"Pottel, H., Adebayo, O. C., Nkoy, A. B. & Delanaye, P. Glomerular hyperfiltration: part 1\u2014defining the threshold\u2014is the sky the limit? Pediatric Nephrol. 38, 2523\u20132527 (2023).","journal-title":"Pediatric Nephrol."},{"key":"3723_CR43","doi-asserted-by":"publisher","first-page":"11980","DOI":"10.3390\/ijms241511980","volume":"24","author":"F Urbano","year":"2023","unstructured":"Urbano, F., Farella, I., Brunetti, G. & Faienza, M. F. Pediatric type 1 diabetes: mechanisms and impact of technologies on comorbidities and life expectancy. Int. J. Mol. Sci. 24, 11980 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"3723_CR44","doi-asserted-by":"publisher","first-page":"e0153033","DOI":"10.1371\/journal.pone.0153033","volume":"11","author":"B Zabeen","year":"2016","unstructured":"Zabeen, B. et al. Insulin pump therapy is associated with lower rates of retinopathy and peripheral nerve abnormality. PLoS ONE 11, e0153033 (2016).","journal-title":"PLoS ONE"},{"key":"3723_CR45","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJM198503073121004","volume":"312","author":"MJ Wiseman","year":"1985","unstructured":"Wiseman, M. J., Saunders, A. J., Keen, H. & Viberti, G. Effect of blood glucose control on increased glomerular filtration rate and kidney size in insulin-dependent diabetes. N. Engl. J. Med. 312, 617\u2013621 (1985).","journal-title":"N. Engl. J. Med."},{"key":"3723_CR46","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","volume":"129","author":"DZ Cherney","year":"2014","unstructured":"Cherney, D. Z. et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 129, 587\u2013597 (2014).","journal-title":"Circulation"},{"key":"3723_CR47","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.2215\/CJN.07700621","volume":"16","author":"DZI Cherney","year":"2021","unstructured":"Cherney, D. Z. I. et al. Kidney effects of empagliflozin in people with type 1 diabetes. Clin. J. Am. Soc. Nephrol. 16, 1715\u20131719 (2021).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"3723_CR48","doi-asserted-by":"publisher","unstructured":"Sridhar, V. S. et al. Efficacy and safety of sotagliflozin in patients with type 1 diabetes and CKD. J. Am. Soc. Nephrol. https:\/\/doi.org\/10.1681\/ASN.0000000540 (2024).","DOI":"10.1681\/ASN.0000000540"},{"key":"3723_CR49","doi-asserted-by":"publisher","first-page":"S283","DOI":"10.2337\/dc25-S014","volume":"48","author":"American Diabetes Association Professional Practice Committee.","year":"2025","unstructured":"American Diabetes Association Professional Practice Committee. 14. Children and Adolescents: Standards of Care in Diabetes\u20142025. Diabetes Care 48, S283\u2013S305 (2025).","journal-title":"Diabetes Care"},{"key":"3723_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2021.108081","volume":"36","author":"K Gaebe","year":"2022","unstructured":"Gaebe, K. et al. Evaluation of novel glomerular filtration rate estimation equations in adolescents and young adults with type 1 diabetes. J. Diabetes Complications 36, 108081 (2022).","journal-title":"J. Diabetes Complications"},{"key":"3723_CR51","doi-asserted-by":"crossref","unstructured":"Favel, K., Irvine, M., Ronsley, R., Panagiotopoulos, C. & Mammen, C. Glomerular filtration rate abnormalities in children with type 1 diabetes. Can. J. Diabetes 46, 457\u2013463.e1 (2022).","DOI":"10.1016\/j.jcjd.2022.01.007"},{"key":"3723_CR52","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/dom.15921","volume":"26","author":"YW Kong","year":"2024","unstructured":"Kong, Y. W. et al. Continuous ketone monitoring: exciting implications for clinical practice. Diabetes Obes. Metab. 26, 47\u201358 (2024).","journal-title":"Diabetes Obes. Metab."},{"key":"3723_CR53","first-page":"R75","volume":"302","author":"SC Thomson","year":"2012","unstructured":"Thomson, S. C. et al. Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat. Am. J. Physiol. 302, R75\u2013R83 (2012).","journal-title":"Am. J. Physiol."},{"key":"3723_CR54","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1111\/apa.12993","volume":"104","author":"N Perrin","year":"2015","unstructured":"Perrin, N. & Berg, U. B. Estimated glomerular filtration rates cannot replace measured GFR in type 1 diabetes patients with hyperfiltration. Acta Paediatr. 104, 730\u2013737 (2015).","journal-title":"Acta Paediatr."},{"key":"3723_CR55","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group.","year":"2024","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 105, S117\u2013S314 (2024).","journal-title":"Kidney Int."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03723-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03723-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03723-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T18:54:52Z","timestamp":1757184892000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03723-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,6]]},"references-count":55,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["3723"],"URL":"https:\/\/doi.org\/10.1038\/s41591-025-03723-6","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,6]]},"assertion":[{"value":"20 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"F.H.M. receives research support from the Canadian Institutes of Health Research (CIHR) and Breakthrough T1D (formerly Juvenile Diabetes Research Foundation (JDRF) Canada). P.B. receives salary and research support from the National Institutes of Health (National Institute of Diabetes and Digestive and Kidney Diseases and National Heart, Lung, and Blood Institute), Breakthrough T1D (formerly JDRF) and the American Heart Association. P.B. also receives research support from the University of Washington Medicine Diabetes Institute and Seattle Children\u2019s Research Institute and holds the Raisbeck Endowed Chair of Diabetes Research at the University of Washington. P.B. reports serving or having served as a consultant for AstraZeneca, Bayer, Bristol Myers Squibb, Boehringer Ingelheim, Eli Lilly, LG Chemistry, Sanofi, Novo Nordisk and Horizon Pharma. P.B. also serves or has served on advisory boards and\/or steering committees of AstraZeneca, Bayer, Boehringer Ingelheim, Novo Nordisk and XORTX. P.B. reports grant funding from AstraZeneca, Novo Nordisk, Eli Lilly, Boehringer Ingelheim and Horizon Pharma. D.Z.I.C. is the Gabor Zellerman Chair in Nephrology Research at the University of Toronto and was supported by a Department of Medicine, University of Toronto, Merit Award. He receives support from the CIHR, Diabetes Canada and the Heart & Stroke\/Richard Lewar Centre of Excellence in Cardiovascular Research. D.Z.I.C. is also the recipient of a 5-year CIHR\u2013Kidney Foundation of Canada Team Grant award with additional support from Breakthrough T1D. D.Z.I.C. has received honoraria from Boehringer Ingelheim\u2013Lilly, Merck, AstraZeneca, Sanofi, Mitsubishi-Tanabe, AbbVie, Janssen, Amgen, Bayer, Prometic Life Sciences, Bristol Myers Squibb, Maze, Gilead, CSL-Behring, Otsuka, Novartis, Youngene, Lexicon, Inversago, GlaxoSmithKline, Biobridge, Vantage, Altimmune and Novo Nordisk and has received operational funding for clinical trials from Boehringer Ingelheim-Lilly, Merck, Janssen, Sanofi, AstraZeneca, CSL-Behring, Lexicon, Novo Nordisk and Bayer. H.J.L.H. reports funding to conduct clinical trials from AstraZeneca, Bayer, Boehringer Ingelheim, Janssen and Novo Nordisk (payments to his institution, the University of Groningen); consulting fees from AstraZeneca, Alexion, Alnylam, Bayer, Boehringer Ingelheim, BioCity Biopharma, Dimerix, Eli Lilly, Gilead, Idorsia, Janssen, Novartis, Novo Nordisk, Roche and Travere Therapeutics (payments to his institution, the University of Groningen); honoraria for lectures from AstraZeneca, Bayer and Novo Nordisk; and support for traveling to and attending the American Diabetes Association meeting and the American Society of Nephrology meeting from AstraZeneca and Eli Lilly (payment to his institution, the University of Groningen). K.L.T. receives salary and research support from the National Institutes of Health (National Heart, Lung, and Blood Institute) and the American Diabetes Association. K.L.T. also receives research support from the Seattle Children\u2019s Research Institute. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}